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I on admission. Treatment of ACS patients with or without 
modifiable risk factors was similar with regard to interven-
tional therapies and use of antiplatelet agents. In-hospital 
mortality was lower in patients without modifiable risk fac-
tors but in-hospital MACCE and 1-year survival was similar. 
 Conclusion: Lack of modifiable risk factors was an indepen-
dent predictor of lower in-hospital mortality but not of
MACCE in patients who presented with ACS. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Cardiovascular disease is the leading cause of death in 
the Western world and accounts for around 40% of all 
deaths in Switzerland  [1] .
 The INTERHEART study, a case-control study which 
was carried out in 52 countries, identified nine poten-
tially modifiable risk factors associated with myocardial 
infarction (MI) in both male and female patients and in 
all age groups: among these, abnormal lipid levels, smok-
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 Abstract 
 Objectives: Little is known about patients without known 
modifiable risk factors presenting initially with acute coro-
nary syndrome (ACS). This study assessed baseline charac-
teristics and outcomes of ACS patients with and without the 
known modifiable risk factors arterial hypertension, dyslip-
idemia, obesity, smoking or diabetes.  Methods: All ACS pa-
tients enrolled in the AMIS Plus Registry between 1997 and 
2010 were analyzed until hospital discharge; a subgroup was 
re-assessed at the 1-year follow-up. Outcome measures were 
in-hospital mortality and major adverse cardiac or cerebro-
vascular events (MACCE) defined as a composite outcome of 
mortality, re-infarction and cerebrovascular events.  Results: 
Of 33,306 patients, 2,125 (6.4%) had none of these modifiable 
risk factors. They were older (males), had less moderate or 
severe comorbidities and were more frequently in Killip class 
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ing, hypertension, diabetes and abdominal obesity were 
found to be the most important modifiable risk factors 
for MI  [2, 3] . However, several previous studies have 
shown that patients with chest pain may often lack mod-
ifiable risk factors  [4–6] and some reports have suggested 
that the presence or absence of modifiable risk factors for 
coronary artery disease was not clinically helpful in the 
diagnosis or exclusion of acute MI (AMI) in the emer-
gency department  [4] . For the patients presenting to the 
emergency department, modifiable risk factors do not in-
crease the risk of acute ischemia and convey minimal risk 
for an acute cardiac event  [6, 7] . Use of the cardiac modi-
fiable risk factor burden, defined as the number of risk 
factors present, is not appropriate for defining the prob-
ability of patients with an acute coronary syndrome 
(ACS), especially in those  1 40 years  [4, 5] . Body et al.  [4] 
reported that 12.2% of emergency room patients with 
chest pain but without modifiable risk factors had a final 
diagnosis of AMI.
 Little is known about patients without known modifi-
able risk factors who presented with ACS. Therefore, the 
aim of this study was to assess baseline characteristics 
and outcome in patients without known modifiable risk 
factors admitted with ACS in Switzerland between 1997 
and 2010, and compare them to patients with one or more 
risk factor(s).
 Patients and Methods 
 The AMIS (Acute Myocardial Infarction in Switzerland) Plus 
project, which was started in 1997, is an ongoing nationwide pro-
spective registry of patients admitted with ACS to hospitals in 
Switzerland. Details have been published previously  [8–11] . Par-
ticipating centers, ranging from community care institutions to 
large tertiary care facilities, provide blinded data for each patient 
through a standardized internet- or paper-based questionnaire. 
These are checked for plausibility and consistency by the AMIS 
Plus Data Center in the Institute of Social and Preventive Medi-
cine at the University of Zurich. The registry was approved by the 
Supra-Regional Ethics Committee for Clinical Studies and the 
Swiss Board for Data Security, as well as by the cantonal ethics 
commissions. The AMIS Plus project is officially supported by the 
Swiss Societies of Cardiology, Internal Medicine and Intensive 
Care Medicine.
 For each patient, a total of 230 items are collected by each 
hospital, including medical history, co-morbidities, known car-
diovascular risk factors, clinical presentation, out-of-hospital 
management, early in-hospital management, reperfusion thera-
py, hospital course, diagnostic tests (used or planned), length of 
hospitalization, discharge medication and discharge destina-
tion. Patients are enrolled in the registry on the basis of their 
final diagnosis. The AMIS Plus registry included all patients 
with ACS: AMI defined by characteristic symptoms and/or ECG 
changes and cardiac marker elevation (either total creatine ki-
nase or creatine kinase MB fraction at least twice the upper lim-
it of normal or troponin I or T above individual hospital cutoff 
levels for MI), and unstable angina (symptoms or ECG changes 
compatible with ACS and cardiac marker levels lower than cut-
off or normal levels) according to the new universal definition 
of MI  [12–14] . Patients were also categorized as having ST-seg-
ment elevation MI (STEMI) or non-STEMI (NSTEMI) based on 
initial ECG findings. Classification of STEMI included evidence 
of ACS as described above and ST-segment elevation and/or new 
left bundle branch block on the initial ECG. NSTEMI included 
patients with ischemic symptoms, ST-segment depression or T-
wave abnormalities in the absence of ST-elevation on the initial 
ECG.
 The following modifiable risk factors were included in this 
study: smoking, dyslipidemia, hypertension, diabetes and obesity. 
Modifiable risk factors were documented in the patient’s medical 
history: dyslipidemia (defined as a history of dyslipidemia if diag-
nosed and/or treated by a physician), arterial hypertension (de-
fined as a history of arterial hypertension diagnosed and/or treat-
ed by a physician and/or documented blood pressure  1 140/90 mm 
Hg) and diabetes (defined as a history of diabetes, regardless of 
duration of disease if the patient had been treated for diabetes and 
was previously diagnosed by a physician)  [15] . Documentation of 
the modifiable risk factors provided by the local physicians was 
accepted as stated. A patient was defined as obese if the body mass 
index was  6 30 kg/m 2 and as smoking if the patient was smoking 
at the time of the cardiovascular event. In 2005, a question was 
added to the questionnaire asking patients whether there was a 
family history of premature heart disease in a first-degree relative 
 ! 60 years of age. Co-morbidities of the patients were assessed us-
ing the Charlson comorbidity index  [16] .
 The primary outcome measure was in-hospital mortality. Sec-
ondary outcome measures were the rates of in-hospital major ad-
verse cardiac or cerebrovascular events (MACCE) defined as a 
composite outcome of mortality, re-infarction and cerebrovascu-
lar event as well as 1-year mortality.
 Patient Selection 
 The present analysis included all ACS patients enrolled in 
AMIS Plus between January 1, 1997, and December 31, 2010. ACS 
patients were classified as having no modifiable risk factors if they 
did not have any of the classic modifiable cardiovascular risk fac-
tors (arterial hypertension, dyslipidemia, obesity, smoking or dia-
betes). Furthermore, since 2005, 3- and 12-month follow-ups were 
carried out with patients who gave their informed consent. This 
subgroup of AMIS Plus patients was also analyzed in this study.
 Statistical Analysis 
 The results are presented as percentages for categorical vari-
ables and analyzed using the non-parametric Pearson   2 test or 
Fisher’s exact test as appropriate. Continuous normally distrib-
uted variables are expressed as means  8 SD and compared using 
Student’s two-tailed unpaired t test. Continuous non-normally 
distributed variables are expressed as medians and interquartile 
ranges and analyzed using the Mann-Whitney U test. A proba-
bility value of p  ! 0.05 was considered statistically significant. A 
multivariate logistic regression model based on backward logis-
tic regression methodology was used to determine in-hospital 
mortality predictors from the following set of variables: age, gen-
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der, systolic blood pressure, heart rate, Killip class  1 2 and the 
Charlson comorbidity index. Separate univariate logistical mod-
els were first fitted for each variable and then backward elimina-
tion with a significance level of 0.05 was performed. Odds ratios 
(OR) were simultaneously adjusted for all other predictors in-
cluded in the multivariate logistic regression model. SPSS (ver-
sion 19; SPSS, Chicago, Ill., USA) was used for all statistical anal-
yses.
 Results 
 Between 1997 and 2010, a total of 35,284 patients with 
a final discharge diagnosis of ACS from 77 Swiss hospi-
tals were enrolled in the AMIS Plus Registry. Of these 
patients, 51.2% were treated in large teaching centers and 
48.8% in smaller regional hospitals. Because of incom-
plete data on modifiable risk factors, 1,978 (5.6%) patients 
were excluded from the present analysis. Of the remain-
ing 33,306 patients, 31,181 (93.6%) had one or more mod-
ifiable risk factors, and 2,125 (6.4%) had none of the mod-
ifiable risk factors (smoking, dyslipidemia, hypertension, 
diabetes and obesity;  fig. 1 ). Although the annual rate of 
ACS patients without known modifiable risk factors fluc-
tuated between 4.5 and 7.6% throughout the 14-year pe-
riod, these fluctuations were not significant (p = 0.13; 
 fig. 2 ). ACS patients without modifiable risk factors were 
more likely to have STEMI than patients with one or 
more modifiable risk factors (63.8 vs. 56.9%; p  ! 0.001) 
and more often presented without prior known coronary 
artery disease (77.6 vs. 60.2%; p  ! 0.001).
 Baseline characteristics of the ACS patients according 
to the presence of the modifiable risk factors are reported 
in  table 1 . ACS patients without modifiable risk factors 
were on average 2.4 years older (due to males) than those 
with one or more modifiable risk factors and had less 
moderate to severe comorbidities (Charlson comorbidity 
index  6 2) and were more frequently in Killip class I on 
admission. They presented with comparable delay after 
symptom onset and pain, but they had less frequently 
dyspnea on admission. For the 14,397 patients for whom 
this information was available, a positive family history 
was reported by 26.7% of the patients without modifiable 
risk factors and by 34.5% of patients with modifiable risk 
factors (p  ! 0.001).
ACS patients enrolled in
AMIS Plus 1997–2010
n = 35,284
Patients without modifiable
risk factors
n = 2,125
ACS patients
n = 33,306
Follow-up since 2005
n = 447
Patients with ≥1 modifiable
risk factor(s)
n = 31,181
Modifiable
risk factor(s)
unknown
n = 1,978
Follow-up since 2005
n = 5,290
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 Fig. 1. Flow chart of inclusion data. Modifiable risk factors were 
smoking, hypertension, dyslipidemia, diabetes and/or obesity. 
 Fig. 2. Percentage of ACS patients without 
modifiable risk factors according to ad-
mission year. 
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 Treatment of ACS patients with or without modifiable 
risk factors was similar with regard to interventional 
therapies and use of antiplatelet agents such as thieno-
pyridine and GPIIb/IIIa inhibitors. Patients with modifi-
able risk factors were more likely to receive angiotensin-
converting enzyme inhibitors and/or angiotensin II an-
tagonists and statins but less likely to receive aspirin and 
heparins ( table 2 ).
 Complications and overall outcome were comparable 
between these two patient groups ( fig. 3 ). Crude in-hospi-
Table 1.  Baseline characteristics of the ACS patients (n = 33,306)
ACS patients without
modifiable factors
ACS patients with ≥1
modifiable risk factor
p
value
Patients 2,125 31,181
Males 1,563 (74%) 22,683 (73%) 0.43
Age, years (mean 8 SD)
All 67.3813.0 65.7813.2 <0.001
Males 65.9812.6 63.5812.9 <0.001
Females 71.3813.4 71.4812.3 0.81
Delay, h:min
Median 3:50 4:00 0.32
Interquartile range 1:55 to 11:30 2:00 to 11:45
Resuscitation prior to admission
Cardiopulmonary resuscitation 69/2,082 (3.3%) 1,015/30,415 (3.3%) 0.99
Cardioversion/defibrillation 71/2,082 (3.4%) 1,024/30,284 (3.4%) 0.96
Symptoms on admission
Pain 1,793/2,088 (85.9%) 25,660/30,324 (84.6%) 0.13
Dyspnea 488/2,023 (24.1%) 7,959/28,375 (28.0%) <0.001
Vital signs on admission (mean 8 SD)
Systolic blood pressure, mm Hg 133825 137828 <0.001
Diastolic blood pressure, mm Hg 79816 80818 0.003
Heart rate, beats/min 78821 79820 0.012
ECG on admission
ST-elevation 1,304/2,123 (61.4%) 16,542/31,075 (53.2%) <0.001
ST-depression 463/2,073 (22.3%) 7,737/30,090 (25.7%) 0.001
Left bundle branch block 71/2,122 (3.3%) 1,525/31,058 (4.9%) 0.001
Q-waves 343/2,122 (16.2%) 5,256/31,074 (16.9%) 0.39
Killip class n = 2,114 n = 30,845 0.004
I 1,717 (81.2%) 24,044 (78.0%)
II 273 (12.9%) 4,668 (15.1%)
III 82 (3.9%) 1,312 (4.3%)
IV 42 (2.0%) 821 (2.7%)
Type of ACS n = 2,125 n = 31,109 <0.001
STEMI 1,354 (63.7%) 17,701 (56.9%)
NSTEMI 688 (32.4%) 11,665 (37.5%)
UA 83 (3.9%) 1,743 (5.6%)
History of coronary artery disease 443/1,929 (22.4%) 11,409/28,651 (39.8%) <0.001
Modifiable risk factors
Smoking 12,437/29,177 (42.6%)
Dyslipidemia 17,679/28,059 (63.0%)
Hypertension 19,669/30,082 (65.4%)
Diabetes 6,791/30,172 (22.5%)
Obesity 5,585/25,368 (22.0%)
Family history (since 2005) 280/1,048 (26.7%) 4,611/13,349 (34.5%) <0.001
Number of risk factors (mean 8 SD) 0 2.180.9 <0.001
Charlson comorbidity index ≥2 (since 2002) 202/1,563 (12.9%) 5,709/22,834 (25.0%) <0.001
U nless indicated otherwise, numbers of patients are shown. p values for Killip class and ACS type indicate trends.
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tal mortality was lower in patients without modifiable risk 
factors (OR 0.79; 95% confidence interval, CI, 0.65–0.96, 
p = 0.021). However, the risk for MACCE was similar in 
the two groups (unadjusted OR 0.85; 95% CI 0.71–1.01, p 
= 0.059). Lack of the modifiable risk factors smoking, dys-
lipidemia, hypertension, diabetes and obesity in patients 
admitted with ACS was an independent predictor of low-
er in-hospital mortality, but failed to reach a statistically 
significant level as a predictor of MACCE ( table 3 ).
 After the acute event, 5,737 ACS patients were fol-
lowed up after a median of 384 days (interquartile range 
370–404 days). A total of 3.3% of patients with one or 
several and 2.9% of patients without any of the modifi-
able risk factors studied died during the follow-up pe-
riod. The adjusted OR for mortality for patients without 
modifiable risk factors was 0.82 (95% CI 0.46–1.46; p = 
0.49).
0
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Pa
ti
en
ts
 (%
)
1.0
2.0
3.0
4.0
5.0
6.0
7.0
9.0
Patients without modifiable risk factors
8.0
4.9
6.2
Cardiogenic
shock
6.0
Re-infarction
2.1 1.9
Stroke
0.9
MACCE
p = 0.021 NS
NS
NS
6.8
8.0
5.5
0.5
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 Fig. 3. In-hospital outcome of ACS pa-
tients. Modifiable risk factors were smok-
ing, hypertension, dyslipidemia, diabetes 
and/or obesity. NS = Not significant. 
Table 2.  Pharmacological treatment and reperfusion according to modifiable risk factors (n = 33,306)
ACS patients without
modifiable risk factors
ACS patients with ≥1
modifiable risk factor
p value
Patients 2,125 31,181
Immediate drug therapy
Aspirin 2,045/2,120 (96.3%) 29,385/31,069 (94.6%) 0.001
Thienopyridine 1,272/2,115 (60.1%) 18,282/30,917 (59.1%) 0.37
GPIIb/IIIa antagonist 5,935/1,817 (32.7%) 8,089/26,262 (30.8%) 0.08
Heparin 1,928/2,118 (91.0%) 27,556/31,009 (88.9%) 0.002
-Blocker 1,426/2,109 (67.6%) 21,414/30,891 (69.3%) 0.10
ACEI/AT antagonist 862/2,109 (41.3%) 15,226/30,725 (49.6%) <0.001
Statin 1,158/1,606 (72.1%) 17,574/23,505 (74.8%) 0.019
Reperfusion
Any PCI (all patients) 1,326/1,853 (71.6%) 19,223/27,018 (71.1%) 0.73
Reperfusion in STEMI
Thrombolysis 246/1,354 (18.2%) 3,089/17,671 (17.5%) 0.53
Primary PCI 741/1,354 (54.7%) 9,715/17,696 (54.9%) 0.91
M odifiable risk factors were smoking, dyslipidemia, hypertension, diabetes and obesity. Unless indicated 
otherwise, numbers of patients are shown. ACEI = Angiotensin-converting enzyme inhibitor; AT = angiotensin 
II receptor; PCI = percutaneous coronary intervention.
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 Discussion 
 In this study, 6.4% of the patients with a final diagno-
sis of ACS had none of the classic modifiable cardiac risk 
factors. This is in accordance with the results from Body 
et al.  [4] who found that 7.4% of patients diagnosed with 
AMI in the emergency department had no modifiable 
risk factors.
 The pathophysiology of the atherosclerotic process has 
been a topic in cardiovascular research and recent results 
showed that even in the absence of significant coronary 
artery disease and conventional modifiable risk factors, 
chronic inflammation may be associated with severe ab-
normalities of the coronary microcirculation  [17, 18] . In 
previous reports, the coronary microcirculation plays a 
crucial role in the outcome of patients with STEMI  [19] . 
 For risk assessment in individual patients, several al-
gorithms have been developed, but their implementation 
in clinical practice is poor  [20] .
 The absence of any modifiable risk factors carried a 
negative likelihood ratio of 0.61 for the diagnosis of MI 
 [4] . However, a lack of modifiable risk factors for coro-
nary artery disease should not prevent physicians from 
seeking to rule out acute MI.
 Assessing a patient’s cardiovascular risk is one of the 
important goals and may help to target individual pa-
tients who are asymptomatic but at sufficiently high risk 
for the development of cardiovascular disease and could 
therefore benefit from preventive interventions  [21] . The 
risk of atherosclerotic cardiovascular disease for those 
with a severe modifiable risk factor burden has been re-
ported to be as high as 52% for men and 31% for women 
at 50 years of age  [22] .
 In this study, patients hospitalized for ACS without 
one of the modifiable risk factors recorded in their chart 
did not differ in outcome from patients with known mod-
ifiable risk factors. Although patients without modifiable 
risk factors were older and more frequently admitted for 
STEMI than patients with one or more modifiable risk 
factors, their in-hospital mortality was statistically sig-
nificantly lower. However, mortality in the sub-group of 
patients followed for a median of 384 days after the initial 
ACS was similar for patients with or without these risk 
factors. Hierarchy and impact of clinical risk factors on 
admission to hospital, such as age and hemodynamic pa-
rameters, played a role in both groups with no change in 
major cardiovascular events, indicating the great impor-
tance of clinical risk stratification on admission.
 Differences in baseline characteristics between the 
patients with and without established modifiable car-
diovascular risk factors were assessed regarding the 
presence of moderate or severe comorbidities, dyspnea 
on admission and the severity of heart failure expressed 
in Killip classes. Male patients without modifiable risk 
factors in this study were on average 2.4 years older than 
those with one or more modifiable risk factors. It could 
be speculated that such patients have later onset of an 
acute ischemic event. In a study by Han et al.  [5] in pa-
tients presenting to the emergency department with 
suspected ACS, predominantly in young ( ! 40 years) but 
not in older patients, the odds of ACS being present in-
creased with increasing number of cardiac risk factors 
identified. However, in both populations of our study, 
only 2% of the patients were  ! 40 years of age.
 Patients admitted with ACS without known risk fac-
tors were treated with an early invasive strategy and with 
thienopyridine and GPIIb/IIIa inhibitors in a similar way 
Table 3. I ndependent predictors of in-hospital mortality and in-hospital MACCE
In-hospital mortality I n-hospital MACCE
OR 95% CI p OR 95% CI p
No modifiable risk factors 0.69 0.52–0.92 0.012 0.79 0.61–1.02 0.065
Age per additional year 1.07 1.06–1.07 <0.001 1.05 1.05–1.06 <0.001
Female gender 1.04 0.91–1.19 0.58 1.09 0.96–1.23 0.17
Killip class >II 4.54 3.89–5.30 <0.001 4.13 3.57–4.77 <0.001
Charlson comorbidity index >2 1.60 1.40–1.83 <0.001 1.62 1.44–1.83 <0.001
Systolic blood pressure (per mm Hg) 0.98 0.97–0.98 <0.001 0.98 0.98–0.98 <0.001
Heart rate (per beat/min) 1.01 1.01–1.02 <0.001 1.01 1.00–1.01 <0.001
Mod ifiable risk factors were smoking, dyslipidemia, hypertension, diabetes and obesity.
 Erne et al. Cardiology 2012;121:228–236234
to those patients with one or more risk factors. Overall 
outcome in hospital as well as 1-year survival was similar 
for both patient groups. Studies on the validation of the 
Thrombolysis in Myocardial Infarction (TIMI) risk score 
have found that the presence of at least three of the five 
modifiable risk factors helps to predict the development 
of early adverse cardiac events  [23, 24] . In this study, how-
ever, the number of patients followed for approximately 1 
year after the initial ACS event was probably too low to 
show differences in cumulative MACCE or mortality ac-
cording to the presence or absence of modifiable risk fac-
tors.
 Limitations 
 Participation in the AMIS Plus registry is voluntary, 
the number of hospitals varied and might therefore not 
be entirely representative of all hospitals in the country 
despite the permanent involvement of  1 70% of all hospi-
tals treating patients with ACS. Usual selection bias and 
confounding parameters of such non-randomized and 
uncontrolled studies should be taken into account in the 
interpretation of the data. The possibility of inaccuracies 
in data entry cannot be totally ruled out and may thus 
create unrecognized biases. Individual on-site auditing at 
the participating centers was only performed sporadical-
ly up until 2010. Since then, external auditing has been 
performed regularly. However, the AMIS Plus database is 
very large and represents hospitals of various sizes and 
equipment over a substantial period of time. Data ques-
tionnaires were always carefully checked by the data 
management center.
 All variables were classified based on the assessment 
of the local investigators. The modifiable risk factors were 
treated as dichotomous variables, which is not physiolog-
ically accurate due to the spectrum of disease severity. A 
total of 1,978 patients (5.6%) were excluded from these 
analyses due to missing data on one or several risk fac-
tors. Furthermore, there were no data stating how long 
the patients had the modifiable risk factors. There were 
no assessments of clinical eligibility for each drug and 
thus failure in the use of certain drugs may reflect con-
traindication for their use.
 Conclusion 
 Patients without any of the classic modifiable risk fac-
tors such as smoking, dyslipidemia, obesity, hypertension 
and diabetes who suffered an ACS were comparable with 
ACS patients with one or more of these modifiable risk 
factors. The differences in baseline characteristics showed 
that ACS patients without modifiable risk factors were 
less likely to have moderate or severe comorbidities, dys-
pnea or Killip class II/III on admission, and male patients 
were significantly older. There were no differences in 
gender, age of female patients, delay or resuscitation prior 
to admission. In addition, coronary reperfusion and an-
tiplatelet therapies were similarly used in patients with or 
without modifiable risk factors. Lack of modifiable risk 
factors was an independent predictor of lower in-hospital 
mortality but not an independent predictor of the com-
posite outcome of re-infarction, stroke and death or 
1-year survival in patients who presented with ACS.
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Schmid); Fribourg: Hôpital cantonal (J.C. Stauffer/S. Cook); 
Frutigen: Spital (K. Bietenhard); Genève: Hôpitaux universitaires 
(J.M. Gaspoz/P.F. Keller); Glarus: Kantonsspital (W. Wojtyna); 
Grenchen: Spital (B. Oertli/R. Schönenberger); Grosshöchstetten: 
Bezirksspital (C. Simonin); Heiden: Kantonales Spital (R. Wald-
burger); Herisau: Kantonales Spital (M. Schmidli); Interlaken: 
Spital (E.M. Weiss); Jegenstorf: Spital (H. Marty); Kreuzlingen: 
Herzzentrum Bodensee (K. Weber); La Chaux-de-Fonds: Hôpital 
(H. Zender); Lachen: Regionalspital (C. Steffen); Langnau im
Emmental: Regionalspital (A. Hugi); Laufenburg: Gesund-
heitszentrum Fricktal (J. Frei/E. Koltai); Lugano: Cardiocentro 
Ticino (G. Pedrazzini); Luzern: Kantonsspital Luzern (P. Erne), 
Kantonsspital Sursee (S. Yoon), Kantonsspital Wolhusen (M. Pe-
ter); Männedorf: Kreisspital (T. Heimes); Martigny: Hôpital ré-
gional (B. Jordan); Mendrisio: Ospedale regionale (A. Pagnamen-
ta); Meyrin: Hôpital de la Tour (P. Urban); Monthey: Hôpital du 
Chablais (P. Feraud); Montreux: Hôpital de Zone (E. Beretta); 
Moutier: Hôpital du Jura bernois (C. Stettler); Münsingen: Regio-
nales Spital Zentrum (F. Repond); Münsterlingen: Kantonsspital 
(F. Widmer); Muri: Kreisspital für das Freiamt (C. Heimgartner); 
Nyon: Groupement hospitalier de l’Ouest lémanique (R. Polikar); 
Olten: Kantonsspital (S. Bassetti); Rheinfelden: Gesundheitszen-
trum Fricktal (H.U. Iselin); Rorschach: Kantonales Spital (M. 
Giger); Samedan: Spital Oberengadin (P. Egger); Sarnen: Kan-
tonsspital Obwalden (T. Kaeslin); Schaffhausen: Kantonsspital 
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(A. Fischer); Schlieren: Spital Limmattal (T. Herren/B. Caduff); 
Schwyz: Spital (P. Eichhorn); Scuol: Ospidal d’Engiadina Bassa 
(C. Neumeier/G. Flury); Solothurn: Bürgerspital Solothurn (A. 
Grêt/R. Schönenberger); St. Gallen: Kantonsspital (H. Rickli);
Tiefenau: Tiefenauspital (P. Loretan); Thun: Spital (U. Stoller); 
Thusis: Krankenhaus (U.P. Veragut); Uster: Spital (E. Bächli); 
Uznach: Kantonales Spital (A. Weber); Wädenswil: Schwerpunkt-
spital Zimmerberg-Horgen (B. Federspiel); Walenstadt: Kanto-
nales Spital (D. Schmidt/J. Hellermann); Wetzikon: GZO Spital 
(M. Graber); Winterthur: Kantonsspital (T. Fischer); Wolhusen: 
Kantonales Spital (M. Peter); Zofingen: Spital (S. Gasser); Zollik-
erberg: Spital (R. Fatio); Zug: Kantonsspital (M. Vogt/D. Ramsay); 
Zürich: Klinik im Park (O. Bertel), Universitätsspital Zürich (M. 
Maggiorini), Stadtspital Triemli (F. Eberli), Stadtspital Waid (M. 
Fischler/S. Christen). 
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